It is well known that there is an increased incidence of thromboembolism (TE) in association with cancer including non-small cell lung cancer [[1],[2]]. Recently, a number of publications have reported an additional 3- to 5-fold increase in risk of TE among both anaplastic lymphoma kinase rearranged (ALK+) and c-ros oncogene 1 rearranged (ROS1+) NSCLC. Most of the studies however had limited number of ALK+ or ROS1+ patients, and did not include a paired NSCLC control group for the calculation of the odds ratio (OR) [[3],[4],7, 8, 9, 10,[15],[17]]. We performed this systematic review with meta-analysis and time-to-event analysis to more precisely estimate the additional increased risk (reported as OR or hazard ratio [HR]) of total thromboembolism (TTE) (venous thromboembolism [VTE] and arterial thromboembolism [ATE]) in ALK+ and ROS1+ NSCLC patients, the incidence rate of TE among ALK+ and ROS1+ NSCLC patients, and to review the risk factors potentially associated with increased TE in these patients. Two investigators (VWZ and SHIO) independently searched two electronic databases (PubMed and Scopus) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement [[19]]. We also searched conference proceedings including the American Society of Clinical Oncology (ASCO) meetings.
Reference link- https://www.lungcancerjournal.info/article/S0169-5002(21)00400-1/fulltext
